B-lymphocyte antigen CD20, T-cell surface glycoprotein CD3, and Thymidylate synthase (CD20-CD3-TYMS)

The target description CD20–CD3 with general cellular targets of 5-FU refers to a combination of distinct therapeutic targets rather than a single molecular entity. CD20 (B-lymphocyte antigen CD20, MS4A1) is a cell surface protein found on B-cells, while CD3 (T-cell surface glycoprotein CD3) is a part of the T-cell receptor complex (UniProt P11836, P07766). Bispecific antibodies targeting both CD20 and CD3, such as Mosunetuzumab and Glofitamab, are designed to redirect T-cells to eliminate malignant B-cells in non-Hodgkin lymphomas (NCI Drug Dictionary). On the other hand, 5-Fluorouracil (5-FU) is a chemotherapy agent that primarily targets Thymidylate Synthase (TYMS), an enzyme essential for DNA synthesis (UniProt P04818, PubChem CID 3385). 5-FU also exerts its effects through incorporation into RNA and DNA, leading to cell cycle arrest and apoptosis in various solid tumors (PubMed PMID: 12743474). Because these targets belong to different therapeutic classes—immunotherapy and antimetabolite chemotherapy—they are typically studied as part of combination regimens rather than as a single fused target. This grouping highlights the intersection of targeted immune engagement and traditional cytotoxic inhibition in modern oncology.

Other names

MS4A1CD3ETYMSCD20CD3Thymidylate synthetase5-FU targets

Bispecific antibodies (e.g., Mosunetuzumab) bridge CD20 on B-cells and CD3 on T-cells to induce T-cell mediated cytotoxicity (NCI Drug Dictionary). 5-Fluorouracil (5-FU) acts as an antimetabolite that inhibits Thymidylate Synthase (TYMS), blocking DNA synthesis, and is also incorporated into RNA and DNA (PubMed PMID: 12743474).